The second time is not the charm for Replimune’s melanoma candidate RP1. | The second time is not the charm for Replimune’s ...

Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech ...

Artificial intelligence has long been seen as a way to supercharge drug development. | Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of ...

A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...

Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

Philips has issued a voluntary recall of software for its Trilogy Evo ventilator ser | Philips issued a voluntary recall of ...

Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...

After Medline pulled off a massive $6.26 billion IPO late last year, the company now finds itself facing serious concerns ...